This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Additional Clinical Data From Two Trials On Actinium Pharmaceuticals Iomab-B To Be Presented At American Society Of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 5, 2012 /PRNewswire/ -- Actinium Pharmaceuticals reported today that data from two abstracts of studies investigating the company's pipeline hematology product Iomab-B will be presented at the American Society of Hematology's (ASH) 54th Annual Meeting and Exposition in Atlanta ( December 8-11, 2012). These abstracts include summaries of data from studies in acute myelogenous leukemia, myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL).

Studies presented at this year's ASH meeting will report the complete Phase 2 data set from a study demonstrating that Iomab-B (monoclonal antibody BC8 labeled with Iodine 131) provides a significant survival benefit for high risk AML patients under age 50.  At the time of the abstract writing, 36% of the patients were surviving progression free for a median of 87 months.  Other data to be presented at the meeting include Phase I dose escalating trial in enabling successful engraftment and complete remissions in transplanting patients who do not have fully matched donors.   All the patients in the trial were successfully transplanted and had a complete remission with survival benefit.

The following abstracts will be presented during the 54th Annual ASH Meeting and Exposition:

Abstract #1924:  A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Saturday, December 8, 2012, 5:30 PM - 7:30 PM (Georgia World Congress Center, Hall B1-B2)

Abstract #4164:  Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs